Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers 1 . Here we show in 104 TNBC cases that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some having only a handful of coding somatic aberrations in a few pathways, whereas others contain hundreds of coding somatic mutations. High-throughput RNA sequencing (RNA-seq) revealed that only approximately 36% of mutations are expressed. Using deep re-sequencing measurements of allelic abundance for 2,414 somatic mutations, we determine for the first time-to our knowledge-in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population. We show that TNBCs vary widely in their clonal frequencies at the time of diagnosis, with the basal subtype of TNBC 2,3 showing more variation than non-basal TNBC. Although p53 (also known as TP53), PIK3CA and PTEN somatic mutations seem to be clonally dominant compared to other genes, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal, cell shape and motility proteins occurred at lower clonal frequencies, suggesting that they occurred later during tumour progression. Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes.
Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers 1 .
Here we show in 104 TNBC cases that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some having only a handful of coding somatic aberrations in a few pathways, whereas others contain hundreds of coding somatic mutations. High-throughput RNA sequencing (RNA-seq) revealed that only approximately 36% of mutations are expressed. Using deep re-sequencing measurements of allelic abundance for 2,414 somatic mutations, we determine for the first time-to our knowledge-in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population. We show that TNBCs vary widely in their clonal frequencies at the time of diagnosis, with the basal subtype of TNBC 2, 3 showing more variation than non-basal TNBC. Although p53 (also known as TP53), PIK3CA and PTEN somatic mutations seem to be clonally dominant compared to other genes, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal, cell shape and motility proteins occurred at lower clonal frequencies, suggesting that they occurred later during tumour progression. Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes.
To understand the patterns of somatic mutation in TNBC, we enumerated genome aberrations at all scales from 104 cases of primary TNBC (Affymetrix SNP6.0, 104 cases; RNA-seq, 80 cases; genome/ exome sequencing, 65 cases: 54 exomes, 15 genomes with 4 overlapping) (Supplementary Table 1 and Supplementary Fig. 1 ), annotated with clinical information (Supplementary Table 2 ). We revalidated 2,414 somatic single nucleotide variants 4, 5 (SNVs) (Supplementary Table 3 ) with targeted deep sequencing to a median of 20,0003 coverage, including 43 non-coding splice site dinucleotide mutations (Supplementary Table 4 ) and 104 genes with 107 indels (Supplementary Table 5 and Supplementary Methods). Notably, the distribution of somatic mutation abundance varies in a continuous distribution among tumours (Fig. 1a ) and seems to be unrelated to the proportion of the genome altered by copy number alterations (CNAs) (Fig. 1b) or tumour cellularity ( Supplementary Fig. 2b ). Although this distribution could be partially explained by a false-negative rate in mutation discovery, others have noted similar distributions in epithelial cancers 6 , suggesting that the total mutation content of individual tumours may be shaped by biological processes or differential exposure to mutagenic influences in the population.
The overall pattern ( Supplementary Fig. 3a, b) of CNA abundance appears similar ( Supplementary Fig. 4 ) to that seen in a larger, independent series of ,2,000 SNP6.0 profiled breast tumours 7 . Among the most frequently observed CNA events (Supplementary Table 6 ) are the tumour suppressor and oncogenes PARK2 (6%), RB1 (5%), PTEN (3%) and EGFR (5%). Here we report intragenic deletions (Supplementary Fig. 5 ) in the PARK2 tumour suppressor 8, 9 , specifically linking PARK2 with TNBC for the first time. Consistent with previous reports in breast cancer 10 , we did not observe frequent recurrent structural rearrangements ( Supplementary Fig. 3d and Supplementary  Table 7) , although we revalidated many individual fusion events involving known oncogenes or tumour suppressors (for example, KRAS, RB1, IDH1, ETV6) (Supplementary Tables 8-10) .
A comparison of RNA-seq data with genomes/exomes data revealed that only 36% of validated somatic SNVs were observed in the transcriptome sequence (Supplementary Table 3 and Supplementary Fig. 2b ). In a recent lymphoma study, similar proportions were observed (137 of 329 somatic mutations expressed in RNA-seq) 11 . As expected, the proportion of low-abundance somatic SNVs observed in RNA is reflected in the distribution of wild-type, heterozygous and homozygous expressed mutations ( Supplementary Fig. 2b ), consistent with the notion that low-abundance alleles may represent rarer clones in the primary tumour. We found 43 splice junction mutations with evidence for an impact on splicing patterns (Supplementary Supplementary Fig. 7 ). This is consistent with observations of frequent functional disruption of the RB-regulated cell cycle network 13 in TNBC. We next searched for mutation enrichment patterns in three ways: by single gene mutation frequency over multiple cases; by the mutation frequency over multiple members of a gene family; and by correlating mutation status with expression networks. First, similar to other studies 14, 15 , p53 is the most frequently mutated gene (Supplementary Table 12 ) with 62% of basal TNBC (determined by gene expression classification with PAM50 (ref. 16 ) analysis on RNA-seq expression profiles) and 43% of non-basal TNBC cases harbouring a validated somatic mutation. We also observed frequent mutations in PIK3CA at 10.2% (7/65), USH2A (Usher syndrome gene, implicated in actin cytoskeletal functions) at 9.2% (6/65), MYO3A at 9.2%, PTEN and RB1 at 7.7% (5/65) and a further eight genes (including ATR, UBR5 (also known as EDD1), COL6A3) at 6.2% (4/65) of cases in the cohort (Fig. 2a) . Considering background mutation rates 17 , p53, PIK3CA, RB1, PTEN, MYO3A and GH1 showed evidence of single gene selection (q , 0.1) (Supplementary Table 13 ). Additional recurrent mutations of note occurred in the synuclein genes (SYNE1 and SYNE2, 9.2% 6/65, recently implicated in squamous head and neck cancers 18, 19 ), BRCA2 (three cases), and several other well known oncogenes (BRAF, NRAS, ERBB2 and ERBB3) with mutations in two cases each. Approximately 20% of cases contained examples of potentially 'clinically actionable' somatic aberrations, including BRAF V600E, high-level EGFR amplifications and ERBB2 and ERBB3 mutations.
In the second approach we searched for statistically overrepresented gene families and protein functions using the Reactome functional protein interaction database 20 (Supplementary Methods). This analysis quantifies gene family involvement through sparse mutation patterns in functionally connected genes, which would be statistically underrepresented by single gene recurrent mutation analysis. The overrepresented pathways (false discovery rate (FDR) , 0.001) included p53-related pathways along with chromatin remodelling, PIK3 signalling, ERBB signalling, integrin signalling and focal adhesion, WNT/cadherin signalling, growth hormone and nuclear receptor coactivators, and ATM/RB-related pathways ( Fig. 3a and Supplementary  Table 14) . We note that the candidate 'driver' MYO3A, a cytoskeleton motor protein involved in cell shape and motility, relates to several pathways upstream and downstream of integrin signalling. The mutated genes include extracellular matrix (ECM) interactions (laminins, collagens), ECM receptors (integrins), several proteins COL22A1 (0.6)
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regulating actin cytoskeleton dynamics (usherin, palladin, multiple myosins) and microtubule motor proteins (kinesins) (Fig. 2a) . All of these contribute to cellular processes that have been functionally implicated in cancer progression; however, a signature of somatic mutation associated with these proteins has not been previously noted in TNBC.
To confirm the mutational spectrum in the general breast cancer population we re-sequenced all exons of 29 genes in an additional 159 breast cancers (82 oestrogen receptor (ER) 1 and 77 ER 2 , tumour and matched normal) (Fig. 2b) , and confirmed that many of the genes found in the discovery cohort were recurrently mutated in an additional population. Whether this pattern of mutation represents the occurrence of disease-modifying mutations, or possibly selection from other processes (for example, transcription-related hypermutation) is unknown. Interestingly, the enrichment of cytoskeletal functions in the somatic aberration landscape is also evident from the copy number and alternative splicing landscapes (Supplementary Fig. 8 ).
Third, we integrated both the CNA and mutation data with expression data to reveal genomic events associated with extreme changes in the transcription of interacting genes 20 (Table 1) , using a bipartite graph-based method (driverNet; Supplementary Methods). The somatic aberrations showing statistically significant association with extreme expression in this analysis (P , 0.05) ( Table 1 and Supplementary Table 15 ) implicate well known oncogenes and tumour suppressors (TP53, PIK3CA, NRAS, EGFR, RB1, ATM) and suggest several new genes of interest, including PRPS2 (a nucleotide biosynthesis enzyme, rank 7), harbouring homozygous deletions in three cases, NRC31 (a glucocorticoid receptor, rank 10) with SNVs in three cases, four PKC-related genes, PRKCZ, PRKCQ, PRKG1 and PRKCE. The gene networks show a partial overlap with driverNet applied to the TCGA ovarian high-grade serous data 21 (Supplementary Table 16 ). Having identified candidate driver genes and significantly overrepresented pathways, we asked how these are distributed among individual tumours by clustering a pathway-patient-mutation matrix ( Supplementary Fig. 9 ). The abundance of implicated pathways can be p53  PIK3CA  USH2A  MYO3A  COL6A3  LAMA2  MYH2  DNAH5  PTEN  RB1  PALLD  COL12A1  COL7A1  LAMA4  LAMC1  MYO15A  MYO5A  MYO5B  MYH3  MYH4  DNAH11  DNAH2  DNAH3  DNAH9  EGFR  BRCA2  ERBB2  ITGA10  ITGA2  ITGA2B  ITGA6  ITGA8  ITGAE  ITGAV  ITGB4  COL11A1  COL22A1  COL4A1  COL5A1  COL9A1  LAMA1  LAMB1  LAMB2  LAMB3  LAMB4  LAMC2  LAMP3  MYO1A  MYO9A  MY OC  MYOM2  MYH10  MYH11  MYH6  MYH7  MYH8  MYH9  SA074  SA018  SA073  SA213  SA067  SA093  SA217  SA228  SA069  SA101  SA077  SA219  SA226  SA056  SA097  SA072  SA030  SA051  SA102  SA212  SA089  SA227  SA084  SA236  SA094  SA076  SA234  SA075  SA092  SA214  SA223  SA218  SA215  SA071  SA210  SA083  SA098  SA106  SA054  SA216  SA029  SA229  SA235  SA096  SA237  SA031 LETTER RESEARCH seen to be only partially related to the total number of mutations in a case, groups 1 and 2 having on average fewer mutations per case. The frequent involvement of pathways with p53, PTEN and PIK3CA as members, is noted ( Supplementary Fig. 9) ; however, the case groupings also vary by the progressive inclusion of additional pathways (for example, WNT signalling, integrin signalling, ERBB signalling, hypoxia and PI3K). More than two thirds of cases contained one or more mutations in the actin/cytoskeletal functions group of genes ( Supplementary  Fig. 9 ). Some 12% of cases did not contain somatic aberrations in any of the frequent drivers or cytoskeletal genes (Supplementary Table 12 ). This suggests that primary TNBCs are mutationally heterogenous from the outset, with some patients' tumours having a small number of implicated pathways and few mutations, whereas other patients present with tumours containing extensive mutation burdens and multiple pathway involvement. Motivated by the observation that early primary TNBCs show a wide variation of mutation content, we asked whether the clonal composition of these primary cancers is similarly varied. We and others have shown 22, 23 how deep-frequency measurements of allelic abundance can be used to study tumour clonal evolution. Clonal mutation frequency, a compound measure of clonal complexity, (Fig. 4a) can be estimated from allele abundance, once the influence of copy number states, regional loss of heterozygosity (LOH state) and tumour cellularity have been considered (although we note that approximately 68% of SNVs in this study are in diploid, neutral regions). To extend allelic abundance measurements to estimation of clonal frequencies, we implemented a Dirichlet process clustering model (pyclone; Supplementary Methods and Supplementary Fig. 10 ) that simultaneously estimates the genotype and clonal frequency given a list of deeply sequenced mutations and their local copy number and heterozygosity contexts.
Using the set of deeply sequenced (median 20,0003), validated SNVs, our analysis revealed (Fig. 4b) that groups of mutations within individual cases have different clonal frequencies, indicative of distinct clonal genotypes. Remarkably, the tumours exhibit a wide spectrum of modes over clonal frequencies ( Fig. 4b and Supplementary Fig. 11 ), with some cases showing only one or two frequency modes (Fig. 4b) , indicating a smaller number of clonal genotypes, whereas other tumours exhibit multiple clonal frequency modes, indicating more extensive clonal evolution. Consistent with early 'driver gene' status, mutations in known tumour suppressors such as p53 tend to occur in the highest clonal frequency group in most tumours. However, in some cases (for example, SA219, SA236; Fig. 4b, Supplementary Fig. 11 ) p53 resides in lower-abundance clonal frequency groups ( Supplementary  Fig. 12 and Fig. 3a) , suggesting that it was not the founding event. Although the number of clonal frequency modes tends to increase with the number of mutations, the relationship is not strictly linear (Fig. 4c) . To determine whether basal and non-basal cancers differ in their clonality, we compared the distribution of clonal modes (clusters) by case and as an overall distribution, and note that basal TNBCs have more clonal frequency modes than non-basal TNBCs (Fig. 4c) . Both of these distributions emphasize a key observation; namely, that at the time of diagnosis TNBCs already display a widely varying clonal evolution that mirrors the variation in mutational evolution.
Finally, we asked where key pathways appear in the distribution of clonal frequency groups. We examined the clonal frequency of genes in each pathway and ascertained if there was a deviation away from the distribution of clonal frequency for all mutations. As expected, pathways involving p53 and PIK3CA showed significantly skewed distributions (Wilcoxon, q , 0.01; Fig. 3b and Supplementary Fig. 12 ) towards higher clonal frequencies, consistent with their roles in early tumorigenesis ( Fig. 3a and Supplementary Table 17) . Intriguingly, pathways with cytoskeletal genes such as myosins, laminins, collagens and integrins tend to have lower median clonal frequencies, suggesting that somatic mutations in these genes are acquired much later (Fig. 3b) . Notably, the median clonal frequency for Reactome pathway 'p53 pathway feedback loops', including 46 mutations in ATM, ATR, NRAS, PIK3CA, PTEN, SIAH1 and p53,was 73% (Wilcoxon, q 5 0.0007), whereas 'integrin cell surface interactions', including 23 mutations in integrin, laminin and collagen genes, had a median clonal frequency of 42% (Wilcoxon, q 5 0.9569). 
Primary TNBCs are still treated as if they were a single disease entity, yet it is clear they do not behave as a single entity in response to current therapies. Here we show for the first time, using next-generation sequencing mutational profiling methods, that treatment-naive TNBCs display a complete spectrum of mutational and clonal evolution, with some patients' tumours showing only a few somatic coding sequence point mutations with a limited number of molecular pathways implicated, whereas other patients' tumours exhibit considerable additional mutational involvement. Moreover, the clonal heterogeneity of these cancers is also a continuum, with some patients presenting with low-clonality cancers and other cases exhibiting more extensive clonal evolution at diagnosis. In this respect, the basal expression subtype of TNBCs also tends to show higher clonality at diagnosis, although the relationship is not exact.
In clonally evolving tumours, identification of genes by single gene mutation frequency measurements will probably favour early driver genes, because the subsequent involvement of multiple additional pathways during tumour progression is unlikely to be observed as a frequent single gene mutation. The clonality analysis emphasizes this point: known drivers such as p53, PIK3CA and PTEN have among the highest clonal frequencies, whereas mutations in cell shape/motility and ECM-signalling genes appear in the lower clonal frequency groups, distributed over many genes. Although p53 somatic mutations are clearly early events, the clonal frequencies observed in some TNBC suggest that they are not always the first event, raising a question about what drives early clonal expansion in some of these cancers. Our findings suggest that each TNBC at the time of primary diagnosis may be at a very different phase of molecular progression, with possible implications for approaches to the biology of low clonality versus high clonality primary tumours.
METHODS SUMMARY
The genomes and transcriptomes of 104 TNBCs were profiled with Affymetrix SNP6.0 arrays (all cases), RNA-seq (80 cases; Illumina GAII), and whole exome/ genome sequencing (65 cases; tumour and normal DNA). Exomes were obtained using Agilent's Human All Exon SureSelect Target Enrichment System v.1 followed by Illumina GAII sequencing, and whole genomes were sequenced using Life Technologies SOLiD system. Data were analysed using computational approaches to detect somatic SNVs 4, 5 , indels, copy number alterations, gene fusions and gene expression patterns. Predictions were then validated using orthogonal experimental assays, including targeted ultra-deep amplicon sequencing of SNVs to ,20,0003 redundancy. We determined single genes under selection using a statistical approach that considers patient-specific background mutation and transition/transversion rates. Mutations predicted to alter transcriptional profiles were determined using an integrated bipartite graph-based method (driverNet) that associates genomic aberrations with outlying expression patterns informed by predefined pathway gene sets. Disrupted pathways were determined using the Reactome FI Cytoscape plugin. Clonal analysis was performed (cases with .10 mutations) using a Dirichlet process statistical model that simultaneously estimates clonal frequencies and mutation genotype given deeply sequenced somatic SNVs and copy number estimates. Experimental assays and analytical methodology are detailed in the Supplementary Information.
